Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigious | ||
Readability |
H.S. senior Avg
|
New words:
AB, Antitrust, Assembly, bear, bill, billed, carryover, constraint, cPR, CT, customary, DDT, degrader, disallow, disallowed, double, entirety, fulfill, GGL, Glaxo, glaxosmithkline, GSK, HSR, impart, infection, inguinal, Ipilimumab, iv, leiomyosarcoma, lesion, liver, lung, lymph, mechanism, modification, modulation, niraparib, Nivo, Nivolumab, node, olaparib, partner, partnered, partnering, PDX, Pembrolizumab, pharmacologically, placement, POLQ, predominant, PRMT, ratio, RECIST, regression, reopening, rescinded, revert, scarce, shelf, Simon, skin, standalone, steering, substance, sum, synergistic, TGI, thereunder, tiered, tomography, trialin, unconditional, uncured, underwritten, unperformed, upfront, vehicle, waiting, weak, wholly
Removed:
Australia, beneficially, Celgene, China, exciting, exert, feel, impactful, leader, leased, LLC, unsolicited
Filing tables
Filing exhibits
Related press release
IDYA similar filings
Filing view
External links